Table 1.
Patient characteristics
| Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | |
|---|---|---|---|---|---|
| Age, years/sex | 39/male | 47/female | 34/female | 64/female | 34/female |
| Duration of treatment in hospital, d | 34 | 18 | 50 | 49 | 48 |
| Previous therapies | Methylprednisolone | Methylprednisolone, hydroxychloroquine, cyclosporine | Methylprednisolone, hydroxychloroquine, cyclophosphamide | Methylprednisolone, cyclosporine | Methylprednisolone, IVIG, tocilizumab, cyclosporine |
| Underlying autoimmune disease | None | SLE | SLE | AOSD | UCTD |
| Fever | Yes | Yes | Yes | Yes | Yes |
| Lowest Hemoglobin concentration, g/dl | 5.7 | 6.7 | 6 | 5 | 6 |
| Lowest white blood cell count, ×1000 cells per ul | 0.3 | 1.1 | 2 | 0.3 | 0.6 |
| Lowest platelet count, ×1000 cells per ul | 30 | 16 | 98 | 16 | 9 |
| Peak triglyceride concentration, mg/dl | 416 | 391 | 315 | 429 | 176 |
| Lowest fibrinogen concentration, mg/dl | 80 | 77 | 290 | 147 | 90 |
| Peak ferritin concentration, mg/dl | 153 534 | 523 213 | 27 529 | 69 960 | 80 083 |
| Peak AST, U/l | 2089 | 686 | 456 | 1350 | 1506 |
| Peak ALT, U/l | 834 | 191 | 302 | 3048 | 1294 |
| Peak soluble IL‐2 receptor concentration, U/ml | 8280 | 100 600 | 12 880 | 5070 | 7320 |
Abbreviations: ALT, alanine aminotransferase; AOSD, adult‐onset still disease; AST, aspartate aminotransferase; IL‐2, interleukin 2; IVIG, intravenous immunoglobulin; SLE, systemic lupus erythematosus; UCTD, undifferentiated connective tissue disease.